Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Seagen Inc. - Common Stock (NQ:SGEN)

N/A UNCHANGED
Last Price Updated: 4:00 PM EST, Dec 13, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Seagen Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Check Out What Whales Are Doing With SGEN
Via Benzinga
Pyxis Oncology M&A Spotlight Signals Potential Growth Amidst Competitive ADC Landscape: Analyst
RBC Capital Markets has initiated coverage on Pyxis Oncology Inc (NASDAQ: PYXS) with an Outperform rating and a  
Via Benzinga
Why Shares of Zai Lab Limited Were Jumping on Tuesday
Zai Lab's shares benefited from positive clinical trial news. 
Via The Motley Fool
Encouraging Data From Seagen/Genmab's Cervical Cancer Study - Tivdak Success Sets Stage For New Indications
Seagen Inc (NASDAQ: SGEN) and Genmab A/S (NASDAQ: GMAB) released topline data from the Phase 3 innovaTV 301 global trial in recurrent or metastatic cervical cancer patients with disease progression on... 
Via Benzinga
Looking Into Seagen's Recent Short Interest
Via Benzinga
Ambrx Biopharma Has Surged 483% This Year. But It Could Just Be Getting Started.
The company has another update on its prostate cancer program that could further prod shares. 
Via Investor's Business Daily
Here's How Much You Would Have Made Owning Seagen Stock In The Last 10 Years
Via Benzinga
If You Invested $100 In This Stock 15 Years Ago, You Would Have $1,600 Today
Via Benzinga
Seagen Earnings Preview
Via Benzinga
3 Fantastic Stocks to Buy in a New Bull Market
These stocks could be just the ticket if a sustained new bull market is beginning. 
Via The Motley Fool
How To Invest In The Healthcare Sector
If things go wrong with some healthcare companies, investors often justify why they stay in the stock. And when things go right, they can go right in a hurry. Mersana Therapeutics is an example of how... 
Via Talk Markets
Seagen's Positive Trial Outcomes: Analyst Says The Update Might Double Tukysa's Current Market
Earlier today, Seagen Inc (NASDAQ: SGEN) announced that the Phase 3 HER2CLIMB-02 clinical trial of Tukysa (tucatinib) in combination with the antibody-drug conjugate ado-trastuzumab emtansine (Kadcyla)... 
Via Benzinga
Win For Pfizer? Seagen's Cancer Combo Therapy Hits Primary Goal In Late-Stage Breast Cancer Study
Seagen Inc (NASDAQ: SGEN) announced that the Phase 3 HER2CLIMB-02 clinical trial of Tukysa (tucatinib) in combination with the antibody-drug conjugate ado-trastuzumab emtansine (Kadcyla) met its... 
Via Benzinga
3 Cheap Long-Term Stocks That Smart Investors Will Snap Up Now
These cheap long-term stocks are a good way to play the current market uncertainty and round out your portfolio. 
Via InvestorPlace
$1000 Invested In This Stock 15 Years Ago Would Be Worth $17,000 Today
Via Benzinga
How Is The Market Feeling About Seagen?
Via Benzinga
$100 Invested In Seagen 10 Years Ago Would Be Worth This Much Today
Via Benzinga
Here's How Much You Would Have Made Owning Seagen Stock In The Last 20 Years
Via Benzinga
Reata's Acquisition Fits Biogen's Strategy Despite High Cost: Analyst Says High Level Regulatory Scrutiny Not Anticipated
Earlier today, Biogen Inc (NASDAQ: BIIB) agreed to acquire Reata Pharmaceuticals Inc (NASDAQ: RETA) for $172.50 per share in cash, reflecting an enterprise value of  
Via Benzinga
"Rule Breaker Investing" Market Cap Game Show: A Battle of Wits
Sometimes you know the market cap, sometimes you're just guessing. 
Via The Motley Fool
3 Pharma Stocks That AI is Loving in July
Artificial intelligence recommends that these are the three stocks to consider when investing in pharma stocks. 
Via InvestorPlace
3 Healthcare Stocks With Healthy Dividends
These pharmaceutical companies all combine relatively high dividends with safe payout ratios. 
Via The Motley Fool
Activision Stock Jumps As U.S. Judge Clears Hurdle To Microsoft Buyout
Activision stock rocketed after a court allowed Microsoft to proceed with its $69 billion acquisition of the video game publisher. 
Via Investor's Business Daily
From AI to Obesity Drugs - Global Pharma Has $700B For M&A and Investments: Goldman Sachs
Goldman Sachs compiled research suggesting the global pharmaceutical sector has approximately $700 billion available for M&A and investments. This significant financial reserve will be crucial as... 
Via Benzinga
Best Under-the-Radar Stocks: 3 That AI Predicts Will Soar in July
Bard outperformed other AI models and even beat a human reporter in stock picking. It believes these under-the-radar stocks will soar in July. 
Via InvestorPlace
The 7 Most Undervalued S&P 500 Stocks to Buy Now
Undervalued S&P 500 stocks offer the stability of a well-established share at discount prices investors appreciate. 
Via InvestorPlace
5 Biotech Stocks That Could Soar Thanks To These Disruptive Healthcare Technologies
Via Benzinga
3 Millionaire-Maker Biotech Stocks to Buy and Hold Forever
Here are three long-term biotech stock investments that have the opportunity to turn risk -tolerant investors into millionaires. 
Via InvestorPlace
Unlock the Potential of These 7 Cash-Flow Machines
Here are seven high cash flow stocks that provide investors with both growth and value under any economic conditions. 
Via InvestorPlace
How Biotech Stocks Are Revolutionizing Healthcare Investment Opportunities
The field of biotechnology has become a driving force behind groundbreaking medical advancements, offering investors the opportunity to benefit from these innovations. Here are 10 healthcare innovators... 
Via Talk Markets
< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.